key: cord-0956243-2y9kwyxq authors: El‐Qushayri, Amr Ehab; Ghozy, Sherief; Reda, Abdullah; Kamel, Ahmed Mostafa Ahmed; Abbas, Alzhraa Salah; Dmytriw, Adam A. title: The impact of Parkinson's disease on manifestations and outcomes of Covid‐19 patients: A systematic review and meta‐analysis date: 2021-07-14 journal: Rev Med Virol DOI: 10.1002/rmv.2278 sha: ce844ad836e8de3019698021ab150dfc025572bb doc_id: 956243 cord_uid: 2y9kwyxq Parkinson's disease (PD) patients who contracted Coronavirus disease 2019 (Covid‐19) had a decline in motor functions; nevertheless, there is limited evidence on whether PD patients have a higher risk for contracting Covid‐19 or have worse outcomes. This is the first systematic review and meta‐analysis to review the impact of PD on the prognosis of Covid‐19 patients. We performed a systematic search through seven electronic databases under the recommendations of the Preferred Reporting Items for Systematic Review and Meta‐analyses statement (PRISMA) guidelines. The R software version 4.0.2 was used to calculate pooled sample sizes and their associated confidence intervals (95%CI). Finally, we included 13 papers in this study. The pooled prevalence rate of Covid‐19 was 2.12% (95%CI: 0.75–5.98). Fever, cough, fatigue and anorexia were the most common symptoms with a rate of 72.72% (95% CI: 57.3 ‐ 92.29), 66.99% (95% CI: 49.08–91.42), 61.58% (95% CI: 46.69–81.21) and 52.55% (95% CI: 35.09–78.68), respectively. The pooled rates were 39.89% (95% CI: 27.09–58.73) for hospitalisation, 4.7% (95% CI: 1.56–14.16) for ICU admission and 25.1% (95%CI: 16.37–38.49) for mortality. On further comparison of hospitalisation and mortality rates among Covid‐19 patients with and without PD, there were no significant differences. In conclusion, the prevalence and prognosis of Covid‐19 patients seem comparable in patients with PD and those without it. The increased hospitalisation and mortality may be attributed to old age and co‐morbidities. Coronavirus disease 2019 is one of the beta coronaviruses (βCoVs), which has a well-documented propensity of neuroinvasion, including severe acute respiratory syndrome coronavirus (SARS-CoV), 1 Middle East respiratory syndrome-related coronavirus (MERS-COV), 2 human coronavirus 229E, 3 (HCoV-OC43). 4, 5 In some earlier studies, SARS-CoV particles were found in the brain of SARS patients, [6] [7] [8] which was also experimentally produced through intranasal injection of SARS-CoV 5 or MERS-COV, 2 passing through the olfactory nerves. 5 Although the exact route of SARS-CoV or MERS-COV reaching the brain is unknown, nonneurological routes are not probable since no viral particles were detected in non-neuronal cells of infected brain regions. [6] [7] [8] Viral invasion of the terminal nerves followed by trans-synaptic transfer to the central nervous system is well-documented for haemagglutinating encephalomyelitis virus 67 (HEV67) [9] [10] [11] [12] and avian bronchitis virus, 13, 14 which are members of the corona family. 5, 15 Noteworthy, the HEV67 shares over 91% homology with HCoV-OC43. 16, 17 Taken together, SARS-CoV-2 mostly has the same neuroinvasive propensity documented in other CoVs. In general, Covid-19 neurological manifestations were evident in many patients since the very beginning of this pandemic, ranging from mild headache, nausea, vomiting, and up to generalised seizure and altered consciousness. [18] [19] [20] [21] [22] [23] Less frequent, yet important, manifestations include seizures, strokes of multiple etiologies, and Guillain-Barre syndrome. [20] [21] [22] 24, 25 The possible neuroinvasive mechanism may help explain the respiratory failure in COVID-19 patients; the median time from the first symptom to respiratory deterioration (5-8 days) is enough for viral particles to infiltrate the brain and disrupt medullary neurons. 5, 10 The Covid-19-related case fatality is higher among vulnerable groups such as older age groups and those with co-morbidities. [26] [27] [28] Individuals with Parkinson's disease (PD) show multiple patterns of vulnerability, being advanced in age, mostly have age-related chronic conditions, and related polypharmacy burden. 29 The current literature shows that PD patients who contracted Covid-19 had a decline in motor functions and stress-induced psychiatric problems (e.g., anxiety and mood changes) 30 Duplication between database results was removed using EndNote X8 software. Four authors independently reviewed search results from the title and the abstract considering our inclusion and exclusion criteria in a preformed excel sheet, all original papers reporting patients with PD and Covid-19 were included. We made no restrictions for the language, country, study design, age, sex, or ethnicity of patients. Reviews, animal studies, papers with overlapping data, incomplete data or not reliable for extraction, case reports, case series less than five patients and papers including the same patients in a previously included paper were all excluded. We performed another phase of full-text screening to get the final included studies and identify papers eligible for the analysis. A study was included when all the reviewers agreed to include it; whenever contradiction was found, a discussion was held to resolve the conflict using a senior reviewer if needed. We developed a data extraction form using Microsoft Excel-based on the type of data in our included papers. The extraction sheet consisted of three domains. The first one included study ID, study design, sample size, age, male prevalence, and method of Covid-19 diagnosis. The second part included our outcomes of interest (prevalence of Covid-19 in PD, the prevalence of mortality, hospitalisation, intensive care unit (ICU) admission, length of hospital stay, manifestations, and comorbidities in PD patients with . The third part included the quality rating of the included studies. Three authors independently extracted the data from included papers using the formed excel sheet. Another fourth author was added to recheck the extracted data. A discussion was held to solve any disputations. Upon reaching the final extracted data, we made another phase of checking to ensure the validity of the data. We used the National Institutes of Health (NIH) tool for the methodological quality assessment of included studies. 43 Three independent reviewers evaluated each study using a pre-formed 14 question assessment sheet for the cohort and cross-sectional studies, 12 questions for the case-control studies and nine question assessment sheet for the case series studies. The final decision 2 of 11 -EL-QUSHAYRI ET AL. was based upon a discussion between the reviewers. Depending on the answers to the questions a score was given for each study. Regarding cohort and cross-sectional studies, an 11 to 14 score was considered to have a good quality, a 6 to 10 score was considered to have a fair quality, and below 6 scores were considered to have a low quality. Meanwhile, in case series studies good quality was adopted when the score was 7-9 points, fair quality and poor quality were considered if the score was 3-6 and 0-3 points, in order. For case-control studies, the scores for good, fair and poor quality was reported when the points fall in the range of 10-12, 7-9 and 0-6, respectively. We used R software version 4.0.2 to perform the meta-analysis whenever available. Event rate and the corresponding 95% confidence interval (CI) were used to analyse categorical data. Meanwhile, the pooled mean difference (MD) and the corresponding 95% CI was used to analyse continuous data. The odds ratio (OR) with 95% CI was used to analyse categorical outcomes when outcomes of two compared groups were presented in more than one study. A significant difference was considered when the p value was <0.05. Heterogeneity between studies was evaluated using the I-squared and Q-test, significant heterogeneity was considered when the p-value exceeds 0.1. 44 We used a fixed-effect model under Mantel-Haenszel methods when there was no evidence for heterogeneity; otherwise, a random effect model was used to pool the data. 45 We performed publication bias according to the method of Egger and colleagues if the outcomes were presented in more than 10 studies. 46,47 3 | RESULTS We exported 910 records into endnote after performing the systematic search, of those 89 records were considered as duplicates. F I G U R E 1 Preferred reporting items for systematic review and meta-analyses statement flow diagram of qualitative study selection process EL-QUSHAYRI ET AL. We scanned 829 records for a title and abstract screening followed by a full-text screening of 51 eligible full texts. Finally, we included eight papers from the systematic search in addition to five papers obtained by the manual search making a total of 13 papers [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] ( Figure 1 ). One paper was excluded due to the inclusion of duplicate patients, 61 and another one reported combined outcomes of PD patients combined with parkinsonism patients. 62 Regarding study design, there were five retrospective cohorts, three case-controls, two cross-sectionals, two case series, and one prospective cohort (Table 1) . We included 8649 PD patients and 88710 control subjects. Covid-19 diagnosis was reported in only six papers. One paper was categorised as poor quality while the rest of the papers were categorised as fair quality (Table S1, S2 and S3). Four studies reported the prevalence of Covid-19 in a total of 6878 PD patients. The pooled prevalence rate of Covid-19 was 2.12% (95% CI: 0.75-5.98); nevertheless, heterogeneity was significant among the pooled studies (I 2 = 95%; p < 0.001) with prevalence rates ranging from 0.94% to 8.51% (Figure 2 ). Figure 3 ). Fever, cough, fatigue and anorexia were found to be the most com- In this meta-analysis, we investigated whether PD has a significant impact on the severity and prognosis of Covid-19 infections. Our pooled analysis of the relevant studies showed that the hospitalisation rate for PD patients with Covid-19 infections was 39.89%, while the total mortality rate was 25.1%. Our estimated mortality rate is much higher than the previously reported rates for PD patients from the general population. 63 Akbar et al. 64 conducted a longterm follow-up investigation in the United States to find that among hospitalised patients, the mortality rate for PD was 17%, which was also smaller than the rate for the non-PD included population (22%) over 32 years. A previous systematic review by Macleod et al. 65 reported that among 88 studies, the estimated mortality ratio ranged between 0.9 and 3.8%, with this ratio reportedly increasing over time. On the other hand, a previous meta-analysis by Xu et al. 66 co-regulate within non-neuronal cells, knowing that DDC and ACE2 have been found to have a statistically significant genetic coexpression. The role of coronavirus infections in inducing neurodegeneration in PD might also be another explanation for a potential association between Covid-19 and PD as it has been previously reported that antibodies against previous coronaviruses were observed within the cerebrospinal fluid of the infected patients with PD more frequently than other neurological diseases. 71 PD patients with Covid-19 infections have relatively high mortality and hospital admission rates. However, the impact of PD on these outcomes is not statistically significant. Being diabetic and immunocompromised, among other co-morbidities, were significant predictors for catching Covid-19 infections in our PD population. Further worldwide studies are encouraged for further validation of the current evidence. None. None. Amr Ehab El-Qushayri and Sherief Ghozy were responsible for the idea and the study design. All authors extracted the data. Sherief Ghozy performed the analysis. All authors shared in the manuscript writing, formatting and approval of final version. Data can be requested from the corresponding author upon reasonable request. Amr Ehab El-Qushayri https://orcid.org/0000-0002-0967-797X Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4 Neurotropism of human coronavirus 229E Axonal transport enables neuron-to-neuron propagation of human coronavirus OC43 The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways Multiple organ infection and the pathogenesis of SARS Detection of severe acute respiratory syndrome coronavirus in the brain: potential role of the chemokine mig in pathogenesis Coronavirus infection of rat dorsal root ganglia: ultrastructural characterization of viral replication, transfer, and the early response of satellite cells Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Characteristics of a coronavirus (strain 67N) of pigs Immunofluorescence studies on the pathogenesis of hemagglutinating encephalomyelitis virus infection in pigs after oronasal inoculation The vagus nerve is one route of transneural invasion for intranasally inoculated influenza a virus in mice Morphogenesis of avian infectious bronchitis virus in primary chick kidney cells Neurotropic virus tracing suggests a membranous-coating-mediated mechanism for transsynaptic communication A comparative sequence analysis to revise the current taxonomy of the family Coronaviridae The evidence of porcine hemagglutinating encephalomyelitis virus induced nonsuppurative encephalitis as the cause of death in piglets Central nervous system manifestations of COVID-19: a systematic review Neurologic manifestations of hospitalized patients with coronavirus disease Incidence, characteristics and outcomes of large vessel stroke in COVID-19 cohort: an international multicenter study Association of Guillain-Barre syndrome with COVID-19 infection: an updated systematic review Etiologic subtypes of ischemic stroke in SARS-CoV-2 patients in a cohort of New York city hospitals Epidemiologic features and clinical course of COVID-19: a retrospective analysis of 19 patients in Germany First case of focal epilepsy associated with SARS-coronavirus-2 Neurological manifestations of COVID-19: a systematic review and current update Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy Clinical characteristics of hospitalized individuals dying with COVID-19 by age group in Italy Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study Co-morbidity and polypharmacy in Parkinson's disease: insights from a large Scottish primary care database Parkinson's disease and COVID-19: perceptions and implications in patients and caregivers Adaptive neurology in COVID-19 times Incidence of anxiety in Parkinson's disease during the coronavirus disease (COVID-19) pandemic Knowledge, attitudes, practices, and burden during the COVID-19 pandemic in people with Parkinson's disease in Germany Self-reported needs of patients with Parkinson's disease during COVID-19 emergency in Italy Outcome of Parkinson's disease patients affected by COVID-19 COVID-19 in Parkinson's disease patients living in lombardy The impact of the COVID-19 pandemic on Parkinson's disease: hidden sorrows and emerging opportunities Impact of the COVID-19 pandemic on Parkinson's disease and movement disorders May Parkinson's disease be a protective factor against CNS involvement by SARS-CoV2? Park Relat Disord The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Association of breastfeeding status with risk of autism spectrum disorder: a systematic review, doseresponse analysis and meta-analysis Association of dengue disease severity and blood group: a systematic review and meta-analysis Quality Assessment Tool for Observational Cohort and Cross-Sectional Studies Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration. Available from www.handbook.cochrane.org Statistical aspects of the analysis of data from retrospective studies of disease Comparison of two methods to detect publication bias in meta-analysis Bias in metaanalysis detected by a simple, graphical test Phenomenology and outcomes of in-patients with Parkinson's disease during COVID-19 pandemic COVID-19 Case Fatality and Parkinson's Disease Characteristic of Parkinson's disease with severe COVID-19: a study of 10 cases from Wuhan Risk of hospitalization and death for COVID-19 in people with Parkinson's disease or Parkinsonism Impact of coronavirus disease 2019 pandemic on Parkinson's disease: a cross-sectional survey of 568 Spanish patients COVID-19 in Parkinson's disease: what holds the key? Predictors of COVID-19 outcome in Parkinson's disease Prevalence and impact of COVID-19 in Parkinson's disease: evidence from a multi-center survey in Tuscany region Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study Favourable course in a cohort of Parkinson's disease patients infected by SARS-CoV-2: a single-centre experience The effect of the COVID-19 pandemic on people with Parkinson's disease. J Parkinson's Dis COVID-19 in Parkinson's disease: report on prevalence and outcome Outcome of Parkinson's disease patients affected by COVID-19 COVID-19 in Parkinson's disease patients living in lombardy Unmet needs of people with Parkinson's Disease and their caregivers during COVID-19-related confinement: an explorative secondary data analysis Early predictors of mortality in Parkinsonism and Parkinson disease: a population-based study Incidence and mortality trends of aspiration pneumonia in Parkinson's disease in the United States Mortality in Parkinson's disease: a systematic review and meta-analysis Parkinson's disease and risk of mortality: meta-analysis and systematic review Factors associated with hospitalisation among people with Parkinson's disease -a systematic review and meta-analysis Angiotensin type 2 receptors: role in aging and neuroinflammation in the substantia nigra The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19 Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's disease Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Effects of COVID-19 on Parkinson's disease clinical features: a community-based case-control study: COVID-19 effects on PD symptoms Prevalence and impact of COVID-19 in Parkinson's disease: evidence from a multi-center survey in Tuscany region Outcome of Parkinson's disease patients affected by COVID-19 Infections in patients with diabetes mellitus: a review of pathogenesis Infections in immunocompromised patients from diabetes mellitus Predictors of survival in patients with Parkinson disease. Archives neurology The impact of Parkinson's disease on manifestations and outcomes of Covid-19 patients: A systematic review and meta-analysis